In Phase 2 trials, dosing began at 2 mg once weekly subcutaneously, with incremental increases at approximately 4-weekly intervals up to 12 mg
On April 30, 2026, the FDA proposed to exclude semaglutide from the list of drugs that large-scale compounding pharmacies can produce because the medication is no longer on the shortage list
This study supports the notion that SDF-1 is upregulated during myocardial ischemia and contributes to mobilization of bone marrow derived stem cells to the ischemic heart
In contrast, daily bolus injections of TZP/Sema showed greater inter-animal variability, suggesting less consistent glycemic control
2 Min Read A recent study featured in the medical journal Nature Medicine has indicated that semaglutide, a medication used for treating diabetes and aiding weight loss, can reduce the likelihood of major heart issues by 20%
In clinical trials: 2.5% of Wegovy users developed gallbladder-related disorders 1.0% of placebo users developed similar problems Gallstones specifically occurred in 1.6% of Wegovy users vs
